Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for…
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions
HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Caliber, a leading global provider…
Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity
HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore…
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk…
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc.…
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
July 18, 2025 16:05 ET | Source: HOOKIPA Pharma Inc. NEW YORK…
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting – Urges Stockholders to Vote FOR Approval of Dissolution Proposal
Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current…
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
July 04, 2025 03:00 ET | Source: Nxera Pharma Tokyo, Japan and…
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting – Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.…
